However, this recommendation may not only bene t individual patients, but also may in uence public health interventions and policymakers to consider targeting reductions of sodium in the food supply. Although this may require buy-in from key stakeholders, policy changes, and investment of public health resources, the Work Group believes that the health bene ts of such changes are also likely to be experienced by a wider population than those with CKD alone. Considerations for implementation. This recommendation places high value on evidence linking short-term changes in sodium intake with reductions in BP in CKD populations, and extrapolation of long-term bene ts from the general population. Although there is limited evidence from RCTs about the long-term bene ts or harms of sodium reduction in CKD populations per se, the Work Group agrees, with few exceptions, that there is little evidence or likelihood that health bene ts observed in the general population should not apply to CKD patients. On the contrary, there is reason to believe that the health bene ts of dietary sodium reduction may be particularly bene cial in CKD patients. Persons with CKD are commonly hypertensive, and systematic reviews have suggested that the magnitude of BP reduction for a given degree of reduction in dietary sodium intake is magni ed in hypertensive individuals, particularly if usual sodium intake is high.43 CKD populations also have high risk of CV disease and may therefore have a greater absolute risk reduction of such events with dietary sodium reduction, if the relative bene ts in the general population are indeed applicable to CKD. 